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Developing new methods to treat heart diseases is always a focus for basic research
and clinical applications. Existing drugs have strong side-effects and also require
lifetime administration for patients. Recent attempts of using nanoparticles (NPs) in
treating atherosclerosis in animals and some heart diseases such as heart failure
and endocarditis have provided hopes for better drug delivery and reducing of drug
side-effects. In this mini-review, we summarize the present applications of using
gold nanoparticles (GNPs) as a new drug delivery system in diseased hearts and
of the assessment of toxicity in using GNPs. We suggest that conjugating existing
clinical drugs with GNPs is a favorable choice to provide “new and double-enhanced”
potentiality to those existing drugs in treating heart diseases. Other applications of using
NPs in the treatment of heart diseases including using drugs in nano-form and coating
drugs with a surface of relevant NP are also discussed.
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INTRODUCTION
Heart diseases such as heart failure (HF) cause millions of deaths each year (Yancy et al., 2013).
Although existing drugs can be used as the first step to delay the development of symptomatic
HF, unfortunately the treatment normally cannot effectively control the process of developing
HF. Once symptoms develop, patients will have to take drugs for a lifetime in order to improve
functional status as well as prognosis, but strong side-effects of these drugs are a remaining concern.
Although cardiac transplantation is the most accepted surgical intervention option for end-stage
HF, this strategy is tremendously limited. Therefore new treatments are desperately needed.
Nanoparticles (NPs) have been successfully used for both in vivo and in vitro biomedical
research and applications such as drug manufacture, imaging, biological tagging, anticancer
drugs, drug delivery, antibiotic development, gene transmission, tissue engineering, etc. Gold
nanoparticles (GNPs) especially have been widely used because they are easy to make and stable.
In addition, the gold element itself possesses qualities suitable in a biological-medical area such as
being bioinert, having low toxicity, and low immunogenicity. Recent studies have gained positive
results using NPs treating cancer in clinical trials. For example, pegylated liposomal doxorubicin
HCl (CAELYX/Doxil) was developed and used in metastatic breast cancer phase III clinical trials.
It proved to reduce cardiotoxicity and to have comparable efficacy to conventional doxorubicin
(O’Brien et al., 2004). In skin cancer cells, GNPs help to deliver drugs to target telomerase, directly
halting the growth of the cancer (NCRI, 2016). These accurate deliveries of NPs in cancer treatment
suggest that GNPs may be helpful to deliver drugs to heart muscle cells, even to target mitochondria
without much toxicity.
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In this mini-review, we summarize the present applications of
using GNPs as a new drug delivery system in the treatment of
heart diseases. We firstly summarize studies in the distribution
of GNPs in both normal and diseased hearts, and then assess the
toxicity of using GNPs. We further discussed ways of improving
the efficiency of delivery and suggest that conjugating existing
clinical drugs with GNPs would give “new and double-enhanced”
potential in treating heart diseases, as this makes drug delivery
more efficient and accurate into the heart muscle cells. Other
applications of using NPs in the treatment of heart diseases,
including using drugs in nano-form and coating drugs with a
surface of relevant NP are also identified.
SIZE-DEPENDENT ACCUMULATION OF
GNPs IN NORMAL HEARTS
Better understanding of the distribution of GNPs after
administration in the body especially in the heart is essential
to understand its effects on the heart. Studies have found that
the distribution of GNPs in the heart tissue of normal rats and
mice by single intravenous injection is size-dependent (De Jong
et al., 2008; Sonavane et al., 2008). For a short-term of 24 h
after injection, GNPs with a diameter between 10 and 250 nm
were detected in various organs including heart, whereas the
larger particles were only found in blood, liver and spleen. For
a long-term study of 7 days and several months after injection,
inductively coupled plasma-mass spectrometry (ICP-MS)
detection showed that small GNPs (13 nm) accumulated in
higher levels in the heart compared with GNPs of 4 and 100 nm.
The peak level for these small GNPs (13 nm) occurred at 1 month
in the heart, and remained high at different time points including
30 min, 4 h, 24 h, 7 days, and 1 month; and then dropped
to half at 3 months and almost eliminated at 6 month. This
trend is the same with GNPs of 4 nm, but a reversed trend
was observed for those of 100 nm. The peak of GNPs size of
100 nm occurred at 6 months. Although small GNPs of 13 nm
have favorable accumulation in the heart compared with other
sizes, the whole accumulation of GNPs in the heart is only one
seventh of the amount in the liver, which ranked as the second
high accumulation organ, and one forty-fifth of the amount
in the spleen, which ranked as the first (Cho et al., 2010). By
intra-oesophageal instillation, ultrasmall GNPs (1.4 nm) were
mostly found in the highest accumulation in secondary organs.
When considering the accumulation in the heart, GNPs of
18 nm showed a higher accumulation compared to other sized
particles (Schleh et al., 2012). In conclusion, small GNPs around
13∼18 nm can easily accumulate in the heart.
SIZE-DEPENDENT ACCUMULATION OF
GNPs IN DISEASED HEARTS
Although it has been accepted that small size GNPs can easily
accumulate in normal heart tissue by different methods of
administration, tissue distribution of GNPs in a diseased heart
can be different. A recent study found that GNPs can be enriched
more in ischemic heart tissue and HF than in a normal control.
Lundy et al. (2016) found that the optimal sizes of NPs for passive
targeting of the injured left ventricle immediately following
cardiac ischaemia-reperfusion injury in mice was between 20 and
200 nm. Spivak et al. (2013) found that GNPs of size 30 nm have
higher cardio-protective effects in doxorubicin-induced HF rats
than that induced by Simdax alone. From the aforementioned
experiments, diseased hearts demonstrate that larger sizes of NPs
are accumulated optimally. However, larger GNPs more than
200 nm cannot be used in diseased hearts. Another study (Lundy
et al., 2016) showed that GNPs of 500 nm and larger also have
significantly increased retention in the heart following I/R injury,
but they were shown to be much greater off-target retention
in the spleen. Larger NPs (1 and 2 µm) inside blood vessels
mainly appeared as clusters which may be physically entrapped
within small capillaries of the heart. In conclusion, larger GNPs
can accumulate in diseased hearts better than in normal hearts
and the process is also size-dependent as in normal hearts.
Larger sized GNPs can target the diseased hearts but will become
entrapped within small capillaries.
TOXICITY ASSESSMENT OF GNPs TO
THE HEART
Toxicity of GNPs to the heart has to be fully understood before
using GNPs in the treatment of heart diseases. It is commonly
accepted that no observable toxicity occurs in the kidney or liver
despite the accumulation of gold in these tissues after repeated
administration of GNPs, but whether it will cause toxicity to the
cardiovascular system has not been determined (Rambanapasi
et al., 2016). The length and the mode of GNPs administration,
and particle size are the main factors influencing the toxicity of
GNPs to heart in vivo (Xia et al., 2016). Toxicity of GNPs to
the heart can also be reviewed indirectly by evaluating oxidative
stress and alterations in energy metabolism in animal models.
The results are summarized as below.
The Lengths of Administration
For a sub-acute cardiac toxicity assessment, Yang et al. (2013)
used an isoproterenol (ISO) induced cardiac remodeling model
to investigate the cardiac bio-distribution of polyethylene glycol
(PEG)-coated GNPs (13 nm) and their effects on cardiac
function, structure and inflammation where GNPs were injected
intravenously for seven consecutive days. Their results showed
that under normal physiological conditions the increased
accumulation of GNPs in the heart had no effect on the
function of the heart. Neither did they aggravate ISO-induced
cardiac hypertrophy, cardiac fibrosis, or cardiac inflammation.
For chronic cardiac toxicity evaluation of GNPs in normal mice,
repeated administration of 10 nm PEG-GNPs via tail veins for 14
consecutive days, the LVIDd (left ventricular end-diastolicinner-
dimension), LVMass (left ventricular mass), and HW/BW (heart
weight/body weight) were significantly increased; but there are
no changes for 4 or 12 weeks. These results indicated that the
accumulation of small size GNPs can induce cardiac hypertrophy
in normal mice, but this effect can be reversed during the washout
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period (Yang et al., 2016). Although these two studies were
both using similar size of small NPs, the administration length
were different and these produced contradictory results regarding
cardiovascular toxicity. The possible reason for this is that the
longer injection period than 7 days may lead to reversible toxicity.
The Modes of Administration
(Abdelhalim, 2011a,b) studied the toxicity of GNPs on heart
tissue in normal rats through intraperitoneal administration.
They discovered that rats treated with GNPs 50 or 100 µl
of 10 and 20 nm sizes for 3 or 7 days demonstrated
congested heart muscle with prominent dilated blood vessels,
scattered and extravasations of red blood cells, focus of muscle
hyalinosis, disturbed muscle fascicles, dense prominent focus
of inflammatory cells infiltrated by small lymphocytes, and few
plasma cells, while rats treated with GNPs 50 or 100 µl of
50 nm size for 3 or 7 days demonstrated normal looking heart
muscle with normal muscle direction and fascicles, and very few
scattered small lymphocytes (Abdelhalim, 2011a,b). The different
levels of toxicity induced by intraperitoneal administration of
GNPs were size-dependent, with smaller NPs inducing greater
toxicity to the heart (Abdelhalim, 2011a,b).
Unlike other cardiovascular disease, HF is mainly developed
by consistent vascular stress, and then eventually leads to heart
muscle cells injury as well as fibrosis proliferation. In this case,
limited in vivo studies showed that intravenous injection with
GNPs is the most promising way for the treatment as GNPs
can then circulate in the vascular system directly without being
cleared during digestion process. Nonetheless, various other
injection modes have also been applied in coronary heart disease
(CHD) using GNPs. CHD often has a fixed injury spot visible on
the heart surface or can be located by ECG presentation, which
made injection of GNPs to the particular point possible.
Measuring Oxidative Stress and Energy
Metabolism Parameters in Serum
Ferreira et al. (2015) showed that GNPs of 10 and 30 nm
sizes can produce oxidative damage after acute and long-term
administration, i.e., for a single intraperitoneal injection or
repeated injections (once daily for 28 days). These were evaluated
by the parameters of oxidative stress and energy metabolism.
Results showed that small size GNPs can cause oxidative damage
regardless of the length of the administration. The reason for this
kind of toxicity is due to DNA damage and alterations in energy
metabolism. This result indicated that prolonged administration
of small size NPs, e.g., over several years, may also lead to heart
toxicity.
Toxicity of Ultra-Small GNPs
One study (Pan et al., 2013) found that exposure to 50 and
100 µM of Au 1.4MS can cause a string-like heart and other
malformations in developing zebrafish embryos. In a patch-
clamp experiment (Leifert et al., 2013), 1.4 nm GNPs failed
electrophysiology-based safety tests using human embryonic
kidney cell line 293 cells expressing human ether-a-go-go-Related
gene (hERG). Although ultra-small GNPs can block hERG
channels in vitro, the high dose of 50 mg/kg in vivo did not block
the channel and give a trace of heart arrhythmia (Leifert et al.,
2013). Due to the fact that NPs can form a protein corona when
confronted with protein-containing solutions like serum or full
blood (Casals et al., 2010; Lacerda et al., 2010), it is suspected that
this process will lead to the enlargement of the diameter of NPs,
making it impossible to block hERG channels in vivo. Therefore
the toxicity of NPs discovered in vitro needs to be clarified before
applying in vivo. The bio-distribution of ultra-small NP in the
heart and its toxicity assessment between in vivo and in vitro
remains to be determined.
In conclusion, the toxicity of GNPs to the heart have
been examined by using well-accepted techniques including
ICP-MS, whole-cell membrane patch-clamp, serum parameter
measurement, etc. Although some results are contradictory, the
most relevant factors requiring serious consideration regarding
its toxicity are the mode of administration, the length of
administration and the size of NPs. Long-term exposure to NPs
and more in vivo studies are required before any conclusions can
be made.
GNPs CONJUGATED WITH CLINICAL
APPROVED DRUGS IN THE TREATMENT
OF HEART DISEASES
The present drugs used in the treatment of heart diseases are
not efficient enough and they also have strong side-effects when
patients are required to take the drugs for the duration of
their lives in order to control the symptoms and make better
prognosis. Making good use of existing drugs and combining
them with GNPs to improve the efficiency of delivery is therefore
an obvious straight forward and a favorable choice. It would
be expected that this conjugation will give “new and double-
enhanced” potentiality to existing drugs as drug delivery into the
heart muscle cells becomes more efficient and accurate in the
conjugation form.
There is only one study using clinical confirmed drugs
conjugated with NPs in the treatment of heart disease. Spivak
et al. (2013) found that GNPs-Simdax and GNPs (30 nm)
both made significant cardio-protective effects in rats with
doxorubicin-induced HF, which is higher than that of Simdax
treatment alone. Moreover, it seems that the effect of GNPs-
Simdax (P < 0.01) is better than GNPs (30 nm; P < 0.05) only,
though there is no difference for rat recovery between GNPs-
Simdax and GNPs (30 nm) to treat HF with GNPs in that
study. It is probably due to the lack of preferential targeting of
GNPs-Simdax than GNPs (30 nm) to target heart tissue.
β-Blockers are another good candidate for this purpose of
making NPs conjugation, even better than Simdax, as it can
counteract many harmful effects of the hyperactivity of the
sympathetic nervous system underlying the volume-overloaded
HF (Ni et al., 2013). Metoprolol is a widely used β-blocker,
we suspect that when Metoprolol is conjugated with GNPs,
it may accumulate much more easily and quickly in heart
tissue then Simdax does, because Metoprolol can specifically
target β1 receptors which are mostly expressed in the heart.
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With GNPs targeting heart tissue in HF more easily, GNPs
conjugated Metoprolol may show a double efficiency. We
are planning to use the widely used β-blocker (Metoprolol)
conjugated with GNPs in treating volume-overloaded HF in
rats. This might improve potential clinical practice, as increasing
the dose of GNPs conjugated Metoprolol is less likely to cause
side-effects on other organs.
OTHER APPLICATIONS OF GNPs IN THE
TREATMENT OF HEART DISEASES
The large surface area-to-volume ratio of GNPs enables their
surface to be coated with hundreds of molecules (including
therapeutics, targeting agents, and antifouling polymers) (Ghosh
et al., 2008). NPs carrying cell growth factors would be useful
to amend the damaged heart tissue in coronary arterially disease
(Nguyen et al., 2015) as it is difficult to target the diseased area of
the heart using traditional administration methods intravenously
and it is also dangerous to administer drugs directly into the
heart.
Other forms of NPs used in cancer treatment, such as using
drugs in nano-form directly and the drug coated with purpose
selected GNPs should also be considered in the treatment of the
heart diseases both in vitro and in vivo.
CONCLUSION
In this mini-review, we conclude that GNPs show a size-
dependent accumulation in both healthy and diseased hearts.
Using GNPs conjugated with clinically approved drugs can have
positive effects or enhance the efficiency of the “existing clinical”
drugs in the treatment of the heart diseases. This effect is possibly
due to the fact that GNPs enable accurate targeting and delivery
of the drugs to the targeted tissues. This ability may be even more
enhanced when GNPs conjugated with “existing clinical” drugs if
there is a specific receptor for the drugs existing in the heart. At
the same time, the toxicity of GNPs to the heart is still not clear
due to the contradictory results in some animal studies.
Gold nanoparticles in the treatment of heart diseases has been
gradually proved to be one of the most promising strategies due
to its accurate delivery ability to the target diseased tissue and the
advantageous ability of carrying drugs with it because of its large
surface area-to-volume ratio (Ghosh et al., 2008). As GNPs can
form a protein corona when confronted with protein-containing
solutions such as serum or full blood (Casals et al., 2010; Lacerda
et al., 2010), this can make the diameter and properties of
GNPs different in vivo from in vitro. The lack of animal studies
also brings contradictory results. Furthermore, whether GNPs
conjugated with drugs exert a better effect than GNPs alone in
the treatment of heart disease is still not very clear. Therefore
the mechanism for this potential double-enhanced delivery of
existing drugs still needs to be further verified. Many puzzles need
to be solved before the application of GNPs in the treatment of
heart disease can go into clinical trials. Therefore, we propose that
a wide range of studies using drugs conjugated with GNPs should
be carried out in a variety of heart diseases animal models in vivo.
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